SCHEMBL2335762

SCHEMBL2335762

O=C(Cl)c1cn2cccnc2n1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.60
KDM4E B2RXH2 11/20 0.60
HPGD P15428 6/20 0.60
RAB9A P51151 11/20 0.46
GAA P10253 5/20 0.46
GLA P06280 4/20 0.46
HSD17B10 Q99714 3/20 0.46
NPC1 O15118 8/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
CYP1A2 P05177 1/20 0.45
MAPT P10636 3/20 0.43
KMT2A Q03164 2/20 0.43
TP53 P04637 1/20 0.43
MEN1 O00255 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
RECQL P46063 1/20 0.41
POLB P06746 3/20 0.41
LMNA P02545 1/20 0.41
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL570407 0.84 ALDH1A1 (0.61) ALDH1A1KDM4EHPGDRAB9AGAA
SCHEMBL1901476 0.83 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDRAB9AGAA
SCHEMBL10162406 0.83 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDRAB9AGAA
SCHEMBL18754841 0.80 KDM4E (0.57) ALDH1A1KDM4EHPGDRAB9AGAA
SCHEMBL10130703 0.79 KDM4E (0.59) ALDH1A1KDM4EHPGDRAB9AGAA
SCHEMBL12200399 0.78 KDM4E (0.55) ALDH1A1KDM4EHPGDRAB9AGAA
SCHEMBL1407731 0.75 KDM4E (1.00) ALDH1A1KDM4EHPGDRAB9AGAA
SCHEMBL7305755 0.75 KDM4E (0.52) ALDH1A1KDM4EHPGDRAB9AGAA
SCHEMBL8811701 0.72 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDRAB9AGAA
SCHEMBL2524283 0.70 PTGS1 (0.72) ALDH1A1KDM4EHPGDRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024220626-A1 SMALL MOLECULE MODULATORS OF OGG1 AZKARRA THERAPEUTICS, INC. (US) 2024-10-24 WO disclosed
EP-3263583-A1 IAP BIR DOMAIN BINDING COMPOUNDS Pharmascience Inc. (CA) 2018-01-03 EP disclosed
EP-2534170-B1 IAP BIR DOMAIN BINDING COMPOUNDS PHARMASCIENCE INC (CA) 2017-04-19 EP disclosed
US-9284350-B2 IAP BIR domain binding compounds PHARMASCIENCE INC. (CA) 2016-03-15 US disclosed
US-20130040892-A1 IAP BIR DOMAIN BINDING COMPOUNDS PHARMASCIENCE INC. (CA) 2013-02-14 US disclosed
EP-2534170-A1 IAP BIR DOMAIN BINDING COMPOUNDS Pharmascience Inc. (CA) 2012-12-19 EP disclosed
WO-2011098904-A1 IAP BIR DOMAIN BINDING COMPOUNDS AEGERA THERAPEUTICS, INC. (CA) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040892-A1 IAP BIR DOMAIN BINDING COMPOUNDS BIRC5, BIRC2, BIRC3 ALDH1A1 4122/4885KDM4E 3728/4885HPGD 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.